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ORIGINAL CONTRIBUTION
The Global Allergy and Asthma European Network 
(GALEN) rhinosinusitis cohort: a large European 
cross-sectional study of chronic rhinosinusitis patients 
with and without nasal polyps*
Background: Chronic rhinosinusitis (CRS) is a common yet under-recognised chronic inflammatory disease of the nose and para-
nasal sinuses that is classified according to the presence (CRSwNP) or absence (CRSsNP) of nasal polyps. 
Methods: This paper reports the methodology and descriptive results of the Global Allergy and Asthma European Network 
(GALEN) rhinosinusitis cohort. We established a large CRS cohort within the GALEN consortium (European FP6 research initiative) 
to identify inflammatory endotypes, the natural disease course, and its impact on health-related quality of life (HRQoL). Detailed 
information on the impact of CRS on HRQoL, comorbidity incidence, objective disease measures, and medical and surgical treat-
ments were collected. 
Results: This multicentre cross-sectional case–control study recruited 935 adults (869 eligible for analysis: 237 CRSsNP; 445 
CRSwNP; 187 controls [reference group]). Comorbidities such as asthma, allergy, eczema, food allergy, urticaria, and chronic ob-
structive pulmonary disease were significantly more frequent in CRS patients. Nasal corticosteroids, antibiotics, and oral cortico-
steroids were the most common treatments. Significantly more CRSwNP patients reported previous sinonasal surgery. 
Conclusions: This study provides detailed information that facilitates studying CRS and its main phenotypes. However, patient 
distribution of this study does not necessarily reflect disease distribution in the general population.
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Introduction
Chronic rhinosinusitis (CRS) is a common yet under-recognised 
chronic inflammatory disease. The prevalence of CRS in various 
European countries ranges from 7 to 27%, with an average of 
10.9% (1). A recent study in the United States estimated that 
prevalence of CRS in the source population was 11.9%; while 
another 17.0% met criteria for past CRS (2).
CRS is pragmatically classified according to the presence 
(CRSwNP) or absence (CRSsNP) of nasal polyps (NP). Using 
patient questionnaires to measure the prevalence of NP yielded 
estimates of 2.1% (France) (3) to 4.3% (Finland) (4) in Europe and 
1.1% in China (5).
Although the aetiology of CRSwNP is largely unknown, CRS-
sNP and CRSwNP are associated with T-cell-mediated immune 
responses. CRSsNP is mostly characterised by fibrosis and mild 
inflammation, and is often associated with Th1 or Th17 inflam-
mation. CRSwNP appears to be associated with moderate or 
severe Th2 eosinophilic inflammation (6–8). However, recent stud-
ies suggest that the molecular diversity of patients with CRS is 
not reflected by simple differentiation into Th1 and Th2 disease 
categories (6).
According to the European Position Paper on Rhinosinusitis 
and Nasal Polyps (EPOS) guidelines (9), patients diagnosed with 
CRS must have ≥ 2 of the following symptoms: mucopurulent 
drainage, nasal obstruction, facial pain or pressure, and partial 
(hyposmia) or total (anosmia) loss of smell; and at least one of 
the following objective measures: documentation of inflam-
mation by mucopurulent drainage, presence of NP and/or 
radiographic imaging showing occupation of paranasal sinuses. 
Considerable overlap exists between the symptoms associated 
with CRSwNP and CRSsNP (10). Similar symptomatology has 
been observed between the 2 groups. However, patients with 
CRSwNP score more frequently and significantly higher on nasal 
symptoms such as rhinorrhoea, nasal congestion or obstruc-
tion, and olfactory deficits (the most discriminant symptom is 
loss of smell) compared with those with CRSsNP (8, 10), who more 
frequently report facial pain (11).
There are reported associations between CRSwNP and other 
comorbidities, with asthma being the most common comorbid 
disease in this population. Up to 66.7% (range 34.0–66.7%) of 
patients with CRSwNP also suffer from asthma (10, 12–15). It has also 
been suggested that up to 25% of CRSwNP patients may have 
undiagnosed asthma (16). Studies have also demonstrated an as-
sociation between CRSwNP and non-steroidal anti-inflammatory 
drug (NSAID) hypersensitivity (17–21). About 15% of CRSwNP 
patients have NSAID hypersensitivity (17). A significant impact on 
health-related quality of life (HRQoL) has been demonstrated in 
several studies in adults with CRSwNP compared with both the 
general population and patients with CRSsNP (22–24).
There are multiple published international guidelines for the 
treatment of CRS, including a European position paper (9) and 
an international consensus statement (25). CRS treatment aims 
to achieve and maintain disease control (26). Disease control 
is reached when patients do not have symptoms or have 
symptoms that are tolerable, with healthy or almost healthy 
mucosa and a lack of need for systemic medication (9). The Global 
Allergy and Asthma European Network (GALEN) consortium 
was created in 2004 to increase interaction between European 
research and clinical institutions, and to improve allergy and 
asthma research (6). Since large cross-sectional studies of CRS 
are lacking, we set up a large rhinosinusitis cohort study within 
the GALEN consortium to identify inflammatory endotypes, the 
natural course of the disease, and its impact on HRQoL in CRS 
patients.
The main objectives of the cohort were: 1) to describe the 
characteristics of the GALEN rhinosinusitis cohort and provide 
detailed information on CRS patients and their differentiating 
criteria; 2) to identify inflammatory endotypes and clinical 
phenotypes; 3) to determine the natural course of the disease, 
including clinical characteristics and patient-reported outcomes; 
and 4) to evaluate the impact of CRS on HRQoL in affected pa-
tients compared with controls, population norms for HRQoL, and 
the variation in HRQoL in different CRS phenotypes. This paper is 
a methodological overview of the GALEN rhinosinusitis cohort.
Materials and methods
Study design and setting
This multicentre cross-sectional case–control study was carried 
out by the GALEN Rhinosinusitis Cohort group (principal inves-
tigator, C. Bachert) within the framework of the European FP6 
research initiative.
The cohort was set up for patients presenting in outpatient ear, 
nose and throat (ENT) clinics at 9 University centres (Ghent, 
Leuven, Amsterdam, Barcelona, London, Berlin, Helsinki, Łódź, 
and Stockholm) in eight European countries (Belgium, the 
Netherlands, Spain, UK, Germany, Finland, Poland, and Sweden). 
The protocol was approved by each participating centre’s ethics 
committee, and patients signed written informed consent prior 
to recruitment between 25 April 2007 and 7 December 2009.
Participants
Adult CRS patients aged 18–60 years conforming to the EPOS 
2007 (27) diagnostic criteria for CRS were recruited at the parti-
cipating centres. Patients listed for inferior turbinate surgery 
without a history or symptoms of CRS or other chronic sinus 
diseases (irrespective of their allergy status) were included as 
unmatched control subjects (reference group). CRS patients 
who had had an exacerbation of allergic rhinitis in the past 2 
weeks, or who had ever had functional endoscopic sinonasal 
surgery (FESS), were excluded from the study. The reference 
group patients were admitted to a tertiary centre and, although 
they did not report any medical history or have any symptoms 
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inflammatory drugs, or other); 3) eczema, including diagnosis 
year, whether ongoing, and current medication; 4) food allergy; 
5) contact allergy; 6) urticaria; and 7) allergic bronchopulmonary 
aspergillosis.
Detailed medical history for lower respiratory conditions was 
collected for: 1) asthma, 2) chronic obstructive pulmonary 
disease (COPD), and 3) recent (within ≤ 3 weeks) bronchial 
infection. 
Comorbid history of autoimmune diseases, diabetes, cystic 
fibrosis, ciliary dyskinesia, upper or lower gastrointestinal tract 
or other recurrent infections, and throat/voice complaints were 
also recorded.
Endoscopic examination
Enrolled patients underwent nasal endoscopy by an ENT or 
allergy specialist at their respective study centre, and the fol-
lowing quantitative or qualitative assessments were performed: 
nasal polyp score (NPS) were scored on a scale of 0–3 for each 
nostril (0, absence of polyps; 1, polyp[s] only in middle meatus; 
2, polyps beyond the middle meatus not blocking the nose 
completely; and 3, polyps completely obstructing the nose), 
leading to a total score range of 0–6 for both nostrils.
CT scan of the paranasal sinuses
If the participant had an available computerized tomography 
(CT) scan of the paranasal sinuses not older than 12 months at 
the time of recruitment, it was scored by an ENT specialist. The 
scoring was based on the Lund–Mackay (LMK) scoring system 
(34). In LMK scoring, the sinuses (maxillary, anterior/posterior 
of CRS, these patients may have nasal symptoms and a disease 
burden that are higher than in the healthy population. Detailed 
inclusion and exclusion criteria are provided in Supplementary 
Table 1.
Participant-reported and investigator-assessed data
Detailed, self-reported information on symptoms and diagno-
sis was collected. Patients reported the year of their first sinus 
complaint, including the specialty of the diagnosing doctor. 
The participants also reported how their sinus problems began 
(headache, loss of smell, common cold, frequent episodes of 
acute sinusitis, or no specific medical history at the start of the 
problem). This list was developed based on expert input.
The participants were provided with the list of main CRS 
symptoms (blocked nose, facial pain/pressure, runny nose, loss 
of smell, mucus in throat, headache, and episodes of acute 
rhinosinusitis), which they then ranked chronologically based 
on when they noticed the symptoms. In addition, the partici-
pants also scored the duration (in months) and frequency (in the 
last month) of these symptoms. The colour of nasal secretions 
(watery and colourless or thick and coloured) was also reported.
Participants reported general disease severity (overall rhinosi-
nusitis) along with the severity of 10 symptoms (blocked nose, 
loss of smell, runny nose, sneezing, headache, facial pain/pres-
sure, post-nasal drip, itchy nose, itchy ears, and itchy throat) and 
episodes of acute rhinosinusitis through a Visual Analogue Scale 
(VAS; 0–10 cm) that can measure both disease and individual 
symptom severity (27). HRQoL was evaluated through the generic 
HRQoL scale, the Short Form-36 (SF-36) (28–31), and a disease-
specific HRQoL scale, the Rhinosinusitis Outcome Measure-31 
(RSOM-31) questionnaire (32, 33).
The details of previous medical and surgical treatments were 
recorded based on participant recall, as history of FESS was 
an exclusion criterion. In addition, current medications (type, 
dose, start/end date/if ongoing) and planned surgery, in those 
for whom it was indicated for the sinus condition, were also 
recorded.
Investigator-assessed patient and disease characteristics
The reporting of investigator-recorded patient characteristics 
and a lung function test (spirometry) for each participant were 
performed by a specialist. The allergic status of the patient 
was assessed by medical history and then confirmed by skin 
prick test using the pan-European allergen panel. In some 
participants, based on the investigator’s decision, a blood assay 
(radioallergosorbent test) or allergen provocation was under-
taken. Medical history of allergic comorbidities was recorded 
for: 1) allergic rhinitis, including its classification based on 
Allergic Rhinitis and its Impact on Asthma guidelines (duration: 
intermittent, persistent; severity: mild, moderate–severe); 2) 
drug allergy or intolerance by type (penicillin, aspirin/other anti-
Figure 1. GALEN Rhinosinusitis Cohort. Patient disposition. CRSsNP, 
chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosi-
nusitis with nasal polyps; GALEN, Global Allergy and Asthma European 
Network;  ID, identification.
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ethmoid, sphenoid, and frontal) were each scored on a scale 
of 0–2 opacification (0, normal; 1, partial opacification; 2, total 
opacification). The ostiomeatal complex was scored on a 2-point 
scale of 0 and 2 (0, not occluded; 2, occluded). The scores on 
each side ranged from 0 (complete translucency of all sinuses) 
to 12 (complete opacity of all sinuses), leading to a total LMK 
score of 24 for both sides.
Biomarker collection and assay
The tissue was analysed for interleukin (IL)-5, interferon (IFN)-γ, 
IL-17A, tumour-necrosis factor (TNF)-α, IL-22, IL-1b, IL-6, IL-8, 
eosinophilic cationic protein, myeloperoxidase, transforming 
growth factor (TGF)-β1, immunoglobulin (Ig)E, Staphylococcus 
aureus-specific IgE, and albumin. The results of the measure-
ments of these inflammatory biomarkers have been published 
previously (6). 
Serum/blood samples, nasal secretions, and nasal mucosal tis-
sues were also collected.
Statistical methods
CRS and reference group patients were planned to be recruited 
at a ratio of 4:1, and each participating centre had a target of 
100 CRS and 25 reference group participants. We analysed the 
CRSwNP, CRSsNP, and reference groups for descriptive com-
parison. Qualitative variables are summarised by counts and 
percentages; quantitative variables are summarised by mean, 
median, range, and standard deviation, and with the number of 
observations for each variable calculated. The denominator for 
percentages of patients is the total number of observations (N).
Means or proportions were tested for differences between 
CRSwNP vs reference group and CRSsNP vs reference group. 
Tests were 2-sided, with a global type I error α of 5%. Qualitative 
and quantitative variables were compared using a permutation 
χ2 test.
Study participants with fewer than 2 completed variables were 
excluded from the analyses. The analyses used observed data. 
No data imputation was done. The statistical programmes used 
for the analyses include R and TANAGRA (35, 36).
Results 
Participants
In total, 935 patients were recruited in random order from the 
9 participating centres at the outpatient ENT clinics. The flow 
chart (Figure 1) provides a description of the patients recruited 
and the sample sizes for analysis. 869 patients were included in 
the analyses. Table 1 provides a description of recruitment by 
centre and country.
Sociodemographic data
A total of 869 participants were eligible for analysis. Among 
these participants, 237 (27.3%) were classified as CRSsNP, 445 
(51.2%) as CRSwNP, and 187 (21.5%) as references. The mean 
age was 40.6 years (range 16–76), 46.8 years (range 16–74), and 
34.3 years (range 15–69) for CRSsNP, CRSwNP, and the reference 
group, respectively (Table 2). There were more males (55.0% 
[n/N: 432/786]) than females in the study (Table 2); most parti-
cipants were Caucasian (95.5% [746/781]), lived in a city (66.2% 
[521/787]) and were employed (95.6%; 738/772). Approximately 
Table 1. GALEN Rhinosinusitis Cohort. Recruitment by centre and country. 
Centre name Country Reference group 
(n = 187), analysed 
patients, n (%)
CRSsNP 
(n = 237), analysed 
patients, n (%)
CRSwNP 
(n = 445), analysed 
patients, n (%)
All 
(n = 869), analysed 
patients, n (%)
Royal National Throat, Nose 
and Ear Hospital
UK
5 (2.7) 1 (0.4) 6 (1.3) 12 (1.4)
University Hospitals Leuven Belgium 17 (9.1) 16 (6.8) 8 (1.8) 41 (4.7)
Karolinska Institutet Sweden 18 (9.6) 28 (11.8) 42 (9.4) 88 (10.1)
Helsinki University Central 
Hospital 
Finland
31 (16.6) 0 59 (13.3) 90 (10.4)
Academic Medical Centre, 
Amsterdam 
Netherlands
17 (9.1) 24 (10.1) 61 (13.7) 102 (11.7)
Hospital Clínic–IDIBAPS Spain 0 8 (3.4) 100 (22.5) 108 (12.4)
Medical Universities of 
Łódź and Kraków 
Poland
28 (15) 16 (6.8) 95 (21.3) 139 (16)
Ghent University Hospital Belgium 43 (23) 48 (20.3) 50 (11.2) 141 (16.2)
Charité – 
Universitätsmedizin 
Germany
28 (15) 96 (40.5) 24 (5.4) 148 (17)
CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps. ; GALEN, Global Allergy and Asthma European 
Network.
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one-third of the participants also reported an environmental 
exposure to gas, dust, fumes, air conditioning, extremes of tem-
peratures, and allergens. Smoking (ever) was reported by 56.9% 
of the participants (448/787), out of which 21.2% were current 
smokers (31.2% of CRSsNP patients, 14.3% of CRSwNP patients 
and 21.3% of the reference group). Current alcohol consump-
tion was reported by 41.9% of the participants (296/707). Mean 
(standard deviation [SD]) duration of symptoms was 11.7 (10.5) 
years, and mean (SD) duration of CRS diagnosis was 9.3 (10.2) 
years; over two-thirds of the participants were diagnosed by an 
ENT specialist and around one-third by a general physician.
Disease severity and HRQoL
The severity of the disease and of individual symptoms was 
determined by VAS. Both CRSsNP and CRSwNP patients had 
moderate-to-severe disease per EPOS criteria, with mean VAS 
scores (SD) of 6.81 (2.34) and 6.40 (2.81), respectively (Table 2). 
CRS impaired HRQoL compared with the reference group, and 
its effect was observed with both the disease-specific (RSOM-
31) and generic (SF-36 Version 1) HRQoL scales. The RSOM-31 
severity scores were significantly higher for CRSsNP (mean 
[SD]: 59.14 [27.42]) patients vs the reference group (mean [SD]: 
38.44 [30.51]; p < 0.00001). Similarly, CRSwNP patients reported 
significantly greater severity (mean [SD]: 60.60 [29.70]) vs the re-
ference group (mean [SD]: 38.44 [30.51]; p < 0.00001), indicating 
that CRS negatively affects patient HRQoL. These results on the 
impact on HRQoL in CRS patients were also observed in the SF-
36 generic HRQoL scale, in which both CRSsNP and CRSwNP pa-
 Table 2. GALEN Rhinosinusitis Cohort. Demographics and baseline characteristics.
Reference group 
n = 187 (21.5% of 
analysed patients)
CRSsNP 
n = 237 (27.3% of 
analysed patients)
CRSwNP 
n = 445 (51.2% of 
analysed patients)
All 
n = 869 (100% of 
analysed patients)
Age, number of observations 180 228 380 788
     Years, mean (SD) 34.3 (12.6) 40.6 (12.6) 46.8 (11.2) 42.1 (12.9)
     Years, median 32 41 48 43
     Range 15–69 16–76 17–74 15–76
Gender, number of observations 179 228 379 786
     Male, n (%) 98 (54.7) 112 (49.0) 222 (58.6) 432 (55)
Duration of symptoms, number 
of observations
14 202 339 555
     Years, mean (SD) 12.1 (10) 9.8 (10.5) 12.8 (10.5) 11.7 (10.5)
     Years, median 8.5 6 10 9
     Range 2–38 0–57 0–47 0–57
Diagnosed since, number of 
observations
9 208 320 537
     Years, mean (SD) 12.1 (12.2) 7.3 (9.9) 10.5 (10.1) 9.3 (10.2)
     Years, median 8 3 8 6
     Range 1–38 0–57 0–50 0–57
VAS rhinosinusitis, n (%) 152 (80.4) 220 (92.8) 341 (76.6) 713 (82.0)
     Score, mean (SD) 3.93 (3.55) 6.81 (2.34)*** 6.40 (2.81)*** 6.0 (3.05)
SF-36 physical (PCS), n (%) 170 (89.9) 219 (92.4) 350 (78.7) 744 (85.6)
     Score, mean (SD) 50.43 (8.45) 42.67 (9.67)*** 45.68 (9.45)*** 45.88 (9.70)
SF-36 mental (MCS), n (%) 170 (89.9) 219 (92.4) 355 (79.8) 744 (85.6)
     Score, mean (SD) 50.03 (9.73) 46.7 (10.69)** 46.86 (11.39)* 47.54 (10.88)
RSOM-31 (severity), n (%) 157 (84.0) 217 (91.6) 336 (75.5) 710 (81.7)
     Score, mean (SD) 38.44 (30.51) 59.14 (27.42)*** 60.60 (29.70)* 55.25 (30.52)
RSOM-31 (importance), n (%) 122 (65.2) 186 (78.5) 270 (60.7) 578 (66.5)
     Score, mean (SD) 58.66 (25.36) 71.07 (21.39)*** 74.41 (22.33)*** 70.01 (30.52)
*p = 0.002; **p = 0.001; ***p < 0.00001 compared with the reference group. CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhi-
nosinusitis with nasal polyps; ; GALEN, Global Allergy and Asthma European Network; RSOM-31, Rhinosinusitis Outcome Measure-31 questionnaire; 
SD, standard deviation; SF-36, Short Form-36; VAS, Visual Analogue Scale. 
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tients had significantly worse physical (p < 0.00001) and mental 
health (p = 0.001) compared with the reference group (Table 2).
Comorbidities
Asthma was one of the most frequent comorbidities reported 
by CRS patients. In this cohort, 20.2% of CRSsNP (44/218) and 
49.6% of CRSwNP (173/349) patients reported asthma, compa-
red with 13.6% of reference group patients (20/147; p < 0.0001 
for CRSwNP vs reference group; Figure 2). The reported preva-
lence of asthma in the EU is 8.2% in adults (37). 
The mean ages of asthma onset were 25.6, 34.0, and 23.9 years 
for CRSsNP, CRSwNP, and reference group patients, respectively; 
73.0%, 91.9%, and 66.7% of CRSsNP (27/37), CRSwNP (113/123), 
and reference group patients (12/18) had late-onset asthma (af-
ter age 12 years), respectively (38) (Figure 3). This difference was 
statistically significant only for CRSwNP patients compared with 
the reference group (p = 0.007), though not for CRSsNP patients 
(p = 0.754).
Nearly half (49.5% of CRSsNP [109/220] and 46.8% of CRSwNP 
[162/346]) of CRS patients reported being atopic, compared 
with approximately one-third of reference group patients (35.8% 
[54/151]). These differences were statistically significant (p = 
0.006 and p = 0.018 for CRSsNP and CRSwNP vs the reference 
group, respectively). Allergic rhinitis was reported by approxi-
mately two-thirds of the participants. Eczema was reported by 
17.5%, 16.5%, and 9.0% of CRSsNP (38/217), CRSwNP (57/345), 
and reference group patients, respectively (13/145; p = 0.033 for 
both CRS patient groups vs reference group). 
Drug allergy (IgE-mediated) was almost twice as common in 
CRSsNP (30.6% [33/108]) and CRSwNP (38.2% [60/157]) patients 
than in the reference group (16.3% [8/49]; p = 0.054, p = 0.004 
for CRSsNP and CRSwNP vs reference group, respectively). 
Among patients with a drug allergy, 51.5% of CRSsNP and 22.0% 
of CRSwNP patients reported a penicillin allergy, compared with 
42.9% of the reference group (p = 0.532 and p = 0.43, respect-
ively). Food allergy was reported by 18.1%, 13.3% and 12.2% 
in CRSsNP (19/105), CRSwNP (20/150) and reference group 
patients (6/49), respectively.
The proportion of patients reporting an aspirin or other NSAID 
hypersensitivity among patients with drug allergy was 9.1% for 
CRSsNP and 55.9% for CRSwNP patients vs 28.6% for reference 
group (p = 0.204 and p = 0.240 for CRSsNP and CRSwNP vs 
reference group, respectively). The details of all comorbidities 
reported by the cohort are shown in Figure 2. 
Objective disease assessment (Spirometry/NPS/LMK score)
Mean (SD) % predicted forced expiratory volume in 1 second 
(FEV1) values were 86.7% (17.27) for CRSsNP (77 total observa-
tions), 88.0% (17.27) for CRSwNP (204 total observations), and 
90.3% (16.27) for the reference group (37 total observations) (p 
= 0.596 CRS vs control), irrespective of their asthma comorbidity. 
FEV1/forced vital capacity (FVC) ratios were < 80% in 43.4% 
of CRSsNP (33/76) and 63.3% of CRSwNP (136/215) patients, 
compared with 39.5% of the reference group (15/38; p = 0.836 
and p = 0.006 for CRSsNP and CRSwNP vs reference group, 
respectively).
Figure 2. GALEN Rhinosinusitis Cohort. Distribution of comorbidities 
among CRSsNP and CRSwNP.
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; compared with the reference group. 
†Among patients with drug allergy. ABPA, allergic bronchopulmonary 
aspergillosis; COPD, chronic obstructive pulmonary disease ; CRSsNP, 
chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosi-
nusitis with nasal polyps; GALEN,  Global Allergy and Asthma European 
Network.
Figure 3. GALEN Rhinosinusitis Cohort. Percentage of patients with 
asthma onset by age group.
*p = 0.007 compared with the reference group. CRSsNP, chronic rhinosi-
nusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal 
polyps; GALEN,  Global Allergy and Asthma European Network.
38
Khan et al.
Sinus involvement, as assessed by LMK CT scan scoring, was 
(mean [SD]) 8.28 [5.12] in CRSsNP patients (n = 187) vs 1.16 
[2.84] for the reference group (n = 31) (p < 0.0001). For CRSwNP 
patients (n = 298), the mean LMK score (SD) was 13.95 (5.52), 
which was also significantly different from the reference group 
(p < 0.0001). 58.3% of CRSsNP patients had an LMK score of ≥ 6 
compared with 90.0% of CRSwNP patients. The distribution of 
LMK scores by sinus involvement is presented in Figure 4.
The NPS was assessed only in CRSwNP patients (n = 332), and 
the mean score (SD) was 3.07 (1.40) out of a maximum possible 
bilateral score of 6.
Medical and surgical treatment patterns
The proportion of patients who reported ever having received 
medical treatment for their sinus condition was 80.6% for CRS-
sNP (175/217) and 96.2% for CRSwNP (330/343) patients com-
pared with 9.2% (13/141) for the reference group (p < 0.00001 
for both CRSsNP and CRSwNP vs reference group; Figure 5). 
Intranasal corticosteroids (INCS) were the most frequently used 
medication, reported by 82.5% of the total cohort (396/480) 
and by 68.9% (111/161), 90.4% (274/303), and 68.8% (11/16) of 
CRSsNP, CRSwNP, and reference groups, respectively (p = 0.018 
for CRSwNP vs reference group; Figure 5). Antibiotics were the 
second most used medication in the cohort (59.4% [278/468]), 
and use was significantly higher in CRSsNP patients vs reference 
group (70.4% [119/169] vs 20.0% [3/15]; p < 0.00001) than in 
CRSwNP patients vs reference group (54.9% [156/284] vs 20.0% 
[3/15]; p = 0.015; Figure 5). The third most frequent medica-
tion reported, oral corticosteroids (OCS; 46.2% [212/459]), was 
reported by 23.5% [38/162], 61.3% [173/282], and 6.7% [1/15] 
of CRSsNP, CRSwNP, and reference group participants, res-
pectively. These differences were significant only for CRSwNP 
patients (p = 0.196 for CRSsNP and p < 0.00001 for CRSwNP vs 
reference group, respectively; Figure 5). Antihistamines were 
used by 21.3% [35/164] of CRSsNP patients, 33.6% [89/265] of 
CRSwNP patients, and 20.0% [3/15] of reference group partici-
pants (Figure 5). Painkillers were used by a significantly higher 
proportion of CRSsNP (40.1% [65/162]; p = 0.010) than CRSwNP 
(27.6% [70/254]; p = 0.123) patients vs reference group (6.7% 
[1/15]) (Figure 5).
Before the scheduled visit, 22.7% [49/216] of CRSsNP and 45.9% 
[155/338] of CRSwNP patients underwent sinonasal surgery. A 
revision sinonasal surgery was reported by 52.2% [23/44] of CRS-
sNP patients and 59.2% [81/137] of CRSwNP patients. Among 
the total population, 0.5% [1/187] of the reference group, 2.5% 
[6/237] of CRSsNP patients and 7.2% [32/445] of CRSwNP pa-
tients had had 4 or more sinus surgeries (Table 3).
Discussion
Currently, two CRS phenotypes can be distinguished – CRSsNP 
and CRSwNP. Several studies have previously attempted to char-
acterise CRSwNP and CRSsNP patients based on inflammatory 
endotypes, microbiological profiles, allergy and comorbid condi-
tions, symptoms, and HRQoL. More recently, using an extensive 
genealogical database linked to medical records, one large 
population-based study has attempted to characterise CRSwNP 
and CRSsNP based on the genetic- and/or environment-
associated risk of carrying the same diagnosis in relatives and 
spouses of patients with these conditions (39). However, these 
Figure 4. Distribution of the LMK scores in (A) CRSsNP patients and (B) 
CRSwNP patients. CRSsNP, chronic rhinosinusitis without nasal polyps; 
CRSwNP, chronic rhinosinusitis with nasal polyps; GALEN,  Global Allergy 
and Asthma European Network.
Figure 5. GALEN Rhinosinusitis Cohort. Treatment patterns. CRSsNP, 
chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosi-
nusitis with nasal polyps; GALEN,  Global Allergy and Asthma European 
Network. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.00001 compared with the refer-
ence group.
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studies were conducted in relatively small numbers of patients, 
and their diagnostic criteria for CRS were not consistent. Other 
studies have included larger numbers of CRS patients. Hopkins 
et al. studied more than 3000 CRS patients. All included patients 
were undergoing sinonasal surgery for both CRSwNP and 
CRSsNP and were followed up for 5 years using the Sino-Nasal 
Outcome Test (SNOT-22) as the principal outcome measure. The 
studies demonstrated that sinonasal surgery is safe and effective 
in reducing the symptoms associated with CRS (40, 41). 
The GALEN rhinosinusitis cohort allows for evaluation of mul-
tiple outcomes for CRS patients (including sociodemographic, 
patient-reported, physician-assessed, and objective scores) in 
addition to inflammatory endotypes.
The present paper reports a methodological overview of the GA-
LEN rhinosinusitis cohort. This study provides detailed informa-
tion on the impact of CRS on HRQoL, incidence of comorbidities, 
objective disease measures, and medical and surgical treatment 
patterns.
The average patients in this study had moderate-to-severe CRS 
and were symptomatic for more than a decade, alluding to 
the chronicity of the disease. There was a significant impact of 
CRS on HRQoL, demonstrated both by the high scores on the 
disease-specific RSOM-31 and the significantly higher burden 
compared with the reference group based on SF-36. SF-36 also 
showed an adverse impact of CRS on both the mental and phy-
sical health of patients. 
Comorbidities were also frequently seen in this cohort compa-
red with the reference group, and nearly half of CRS patients 
suffered from a respiratory allergy. More CRSwNP patients 
reported an aspirin or other NSAID hypersensitivity compared 
with CRSsNP patients and the reference group.
Asthma was more frequent in CRS patients compared with the 
reference group. The difference was statistically significant only 
for CRSwNP patients. A higher proportion of CRS patients had 
impaired lung function, as demonstrated by an FEV1/FVC ratio 
of < 80%, compared with the reference group. This proportion 
was higher than those reporting asthma, suggesting a probable 
under-diagnosis of asthma. CRS patients also had a significantly 
higher prevalence of eczema, drug allergy, and COPD compared 
with the reference group.
The most common treatments for both CRSsNP and CRSwNP 
were INCS, antibiotics and oral steroids. In comparison with the 
reference group, CRS patients are more frequently treated with 
antibiotics. Significant differences were observed between CRS-
sNP and CRSwNP patients compared with the reference group in 
the use of painkillers and OCS, respectively.
Surgery is a frequent treatment option, and approximately a 
quarter of CRSsNP and half of CRSwNP patients reported a pre-
vious operation. Among patients with previous surgery, 59.2% 
of the CRSwNP and 52.2% of the CRSsNP group had at least one 
additional surgery. However, the type and extent of surgery 
performed was not evaluated in this study. 53% of patients with 
CRSsNP and 31.9% of CRSwNP patients had a surgery planned at 
baseline visit.
Tomassen and colleagues (6) reported the identification of 
inflammatory endotypes of CRS, using a phenotype-free ap-
proach, in a subset of the GALEN sinusitis cohort. These analyses 
were performed on 173 CRS patients and 89 control patients, 
for whom sufficient tissue for analysis was available. Patients 
were grouped into 10 inflammatory endotype clusters based 
on immune markers. These were then compared post hoc with 
selected phenotype parameters, such as NP prevalence and 
asthma comorbidity. Three clusters were composed exclusively 
of CRSsNP without asthma, while 3 were composed exclusively 
of CRSwNP with a high proportion of asthma comorbidity.
The GALEN rhinosinusitis cohort is not an epidemiological study, 
and the patients were included in order of random presenta-
tion at the study centres. Patient distribution does not reflect 
distribution of the disease in the general population, but rather 
the specific recruitment patterns of the respective clinics. Al-
though the inclusion criteria specified inclusion of patients aged 
> 18–60 years, 7/869 (0.8%) patients < 18 and 52/869 (6.0%) 
patients > 60 years were also recruited and included in these 
analyses. The study centres were large tertiary ones, which may 
have led to an inclusion bias towards more severe cases and pa-
tients with a higher disease burden. It is also possible that more 
such patients were willing to participate. The reference group 
patients were not healthy, and although they did not report any 
medical history or have any symptoms of CRS, these patients 
may have had a nasal and asthma symptom load that is higher 
than in the healthy population. Moreover, since these patients 
had other ENT conditions, they had VAS severity and RSOM sco-
res that were higher than in the healthy population; half of the 
control group was scheduled for conchectomy/turbinectomy 
(data not shown).
The data were based on recall, and therefore may suffer from a 
recall bias. However, as patients and physicians completed their 
 Patients with 
previous 
surgery, n (%)
Reference 
group 
n = 187
CRSsNP 
n = 237
CRSwNP 
n = 445
1 4 (2.1) 21 (8.9) 56 (12.6)
2 1 (0.5) 11 (4.6) 29 (6.5)
3 0 6 (2.5) 20 (4.5)
4 1 (0.5) 6 (2.5) 32 (7.2)
Table 3. GALEN Rhinosinusitis Cohort. Number of previous surgeries.
CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic 
rhinosinusitis with nasal polyps ; GALEN, Global Allergy and Asthma 
European Network.
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respective sub-questionnaires concurrently, this decreased the 
risks of bias and large variation in the clinical evaluation of the 
patients. 
Conclusion
The GALEN rhinosinusitis cohort allows for the possibility of 
studying CRS and its main phenotypes, being one of the largest 
CRS databases in Europe, and includes data on sociodemo-
graphic variables; environmental exposure; symptom and 
disease chronology; patient-reported outcomes, including 
HRQoL; physician-assessed data, including comorbidities; and 
objective measures such as NPS, CT scans, and lung function. In 
addition, the cohort is also a rich source of multiple biomarkers 
as we move towards precision medicine.
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Supplementary Table 1. Inclusion and exclusion criteria of the GALEN Rhinosinusitis Cohort.
Inclusion criteria
For all subjects 1. The subject understands the study procedures and agrees to participate by signing the consent form. 
2. The subject is male or female between 18 and 60 years of age. 
3. Except for the diagnosis of CRS, subjects must be in good health, free of any clinically significant disease that would interfere 
with the study or procedures or compromise his/her safety.
Diagnosis of CRS (with or without nasal polyps, including fungal disease, cystic fibrosis) is based on the EPOS definition and all patients should 
have:
1. Inflammation of the nose and the paranasal sinuses characterised by 2 or more symptoms (1 should always be a or b)
     a. Nasal congestion/obstruction/blockade
     b. Nasal discharge: anterior/posterior nasal drip
     c. Facial pain/pressure
     d. Reduction/loss of smell
2. And either (1 of the criteria below)
a. Endoscopic signs
       - Nasal polyps
       - Mucopurulent discharge from the middle meatus
       - Oedema/mucosal obstruction primarily in the middle meatus
3. And
     a. CT changes: mucosal changes within the ostiomeatal complex and/or paranasal sinuses
     b. Duration of the disease: > 12 weeks of symptoms
     c. No complete resolution of the symptoms
NB: Patients with antrochoanal polyps were excluded.
Control Control patients are patients undergoing nasal surgery such as septoplasty or septorhinoplasty, who have no medical history 
or symptoms of any form of CRS, nasal polyposis, cystic fibrosis or other chronic sinus disease. Trauma patients and patients 
undergoing transnasal approaches for hypophysectomy and surgery for exophthalmia could be included as controls as well. 
Patients with allergy (sensitisation and clinically relevant allergy) were allowed in the control group, and allergy tests were 
done and documented.
Exclusion criteria
General exclusions
1. Patients with a recent acute exacerbation of rhinosinusitis (past 2 weeks) are not allowed to participate.
2. The subject had former FESS, with removal of parts of the lateral nasal wall. Simple polypectomy, septal or inferior turbinate 
surgery is allowed.
3. Women must not be pregnant or breastfeeding.
4. The subject is a current or recent past abuser of alcohol or illicit drugs.
5. The subject has a history of malignancy, is known to be positive for HIV, or has immunodeficiency or other states that are 
considered to interfere with study conduct or scientific interpretations.
6. Subjects must not be known to have sarcoidosis.
7. Subjects must not be known to have any type of vasculitis (including Wegener).
8. Subjects must not be known to be positive to hepatitis B surface antigen or C antibodies.
9. The subject cannot read or comprehend written material, or is, in the opinion of the investigator, for other reasons unlikely 
to understand and follow the study procedures.
10. The subject is mentally or legally incapacitated preventing informed consent from being obtained.
11. Medication wash-out is mandatory only in case of biopsy, for other patients it is optional (medication wash-out period: oral 
steroids 4 weeks; nasal steroids 4 weeks; anti-leukotrienes 2 weeks).
12. Inhaled corticosteroids for asthma are permitted but should be documented in the questionnaires.
CRS, chronic rhinosinusitis; CT, computerized tomography; EPOS, European Position Paper on Rhinosinusitis and Nasal Polyps; FESS, functional endo-
scopic sinus surgery; GALEN, Global Allergy and Asthma European Network; HIV, human immunodeficiency virus.
